Should I Buy 00013? 00013 2026 Analysis

Should You Buy HUTCHMED (00013) Today? Analysis, Price Targets, and 2026 Outlook.

No data

Growth

Profitability

Efficiency

0 Analyst Rating

Wall Street analysts forecast 00013 stock price to rise

0 Buy

0 Hold

0 Sell

Current: 17.190

Low

Averages

High

Current: 17.190

Low

Averages

High

M Stanley

Overweight

maintain

$97

AI Analysis

2026-05-29

Reason

M Stanley

Price Target

$97

AI Analysis

2026-05-29

maintain

Overweight

Reason

The analyst ratings reflect a generally positive outlook on several biotech stocks, with many being rated as 'Overweight' due to their strong performance and potential for growth. Some stocks have seen upgrades in their target prices, indicating confidence in their future performance. However, a few stocks have been downgraded to 'Equalweight' or 'Underweight', suggesting a more cautious approach for those particular investments.

M Stanley

Overweight

maintain

2026-05-29

Reason

M Stanley

Price Target

2026-05-29

maintain

Overweight

Reason

M Stanley has issued investment ratings for various China biotech stocks, with 'Overweight' ratings for KEYMED BIO-B, INNOVENT BIO, DUALITYBIO-B, ABBISKO-B, ZAI LAB, and VISEN PHARMA-B, indicating a positive outlook. HUTCHMED was downgraded from 'Underweight' to 'Equalweight', suggesting a more neutral stance. LEADS BIOLABS-B and REMEGEN received 'Equalweight' ratings, reflecting a balanced view on their performance.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for 00013

Unlock Now

00013 Should I Buy

00013 Should I Buy

Should You Buy HUTCHMED (00013) Today? Analysis, Price Targets, and 2026 Outlook.

No data

No data

Growth

Profitability

Efficiency

People Also Watch